drugset / Trial / NCT00735371

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00735371

Phase 3 Completed 314 enrolled Shire
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.

Timeline

Start
2008-10-08
Primary completion
2009-04-06
Completion
2009-04-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lisdexamfetamine Dimesylate Small molecule 30 mg
Comparator Lisdexamfetamine Dimesylate Small molecule 50 mg
Comparator Lisdexamfetamine Dimesylate Small molecule 70 mg